• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Liver Cirrhosis - Pipeline Review, Q4 2010 - Product Image

Liver Cirrhosis - Pipeline Review, Q4 2010

  • ID: 1474184
  • December 2010
  • 46 pages
  • Global Markets Direct

Liver Cirrhosis - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Liver Cirrhosis    Pipeline Review, Q4 2010”, provides an overview of the Liver Cirrhosis    therapeutic pipeline. This report provides information on the therapeutic development for Liver Cirrhosis   , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Cirrhosis   . “Liver Cirrhosis   -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Liver Cirrhosis   .
- A review of the Liver Cirrhosis    products under development by companies and universities/research institutes based on information derived from company and READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis Overview
Therapeutics Development
An Overview of Pipeline Products for Liver Cirrhosis
Liver Cirrhosis Therapeutics under Development by Companies
Liver Cirrhosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Liver Cirrhosis Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Norgine Limited
ARQULE, INC
Amsterdam Molecular Therapeutics BV
Intercept Pharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Universities/Institutes Involved in Liver Cirrhosis Therapeutics Development
Liver Cirrhosis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Budesonide + Ursodeoxycholic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nobelzin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Product Description
Mechanism of Action
R&D Progress
Pegintron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegintron + Rebetol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG964 + Pegasys - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Adefovir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adefovir + Glycyrrhizin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adefovir + Lamivudine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norfloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegylated interferon alfa-2a + Ribavirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tetrathiomolybdate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Liver Cirrhosis - Featured News
Oct 26, 2010: Chugai Pharmaceutical Filed For Additional Indication Of Compensated Liver Cirrhosis Related to Hepatitis C For Pegasys, And Antiviral Drug, Copegus,
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos